Zhu Y., Pandya BJ., Choi H.K. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008. Arthritis Rheum. 2011 Oct;63(10):3136-41 doi:10.1002/art.30520..
DOI: 10.1002/art.30520
Шальнова СА., Деев АД., Артамонова ПВ. Гиперурикемия и ее корреляты в российской популяции (результаты эпидемиологического исследования ЭССЕ-РФ). Рациональная фармакотерапия в кардиологии. 2014; 10(2):153-159.
Li O., Li X., Kwong J.S.-W., Chen H., Sun X., Tian H., & Li S. Diagnosis and treatment for hyperuricae-mia and gout: a protocol for a systematic review of clinical practice guidelines and consensus statements. BMJ Open. 2017;7(6):e014928. doi:10.1136/bmjopen-2016-014928..
DOI: 10.1136/bmjopen-2016-014928
Billiet L., Doaty S., Katz J.D., Velasquez M.T. Review of hyperuricemia as new marker formetabolic syndrome. ISRN Rheumatol. 2014;2014:852954. doi: 10.1155/2014/852954..
DOI: 10.1155/2014/852954
Елисеев М.С., Барскова В.Г, Насонова В.А. Клиническое значение метаболического синдрома при подагре. Клин. геронтология. 2006;2:29-33. [Eliseev M.S., Barskova V.G., Nasonov V.A. Clinical significance of metabolic syndrome in gout. Klin. Gerontologia. 2006;2:29-33.] (In Russ).
Clarson L., Chandratre P, Hider S., Belcher J., Heneghan C., Roddy E. & Mallen C. Increased cardiovascular mortality associated with gout: a systematic review and meta-analysis. European Journal of Preventive Cardiology. 2013;22(3):335-343. doi:10.1177/2047487313514895..
DOI: 10.1177/2047487313514895
Kuo C.F., Grainge MJ., Mallen C., Zhang W., Doherty M. Comorbidities in patients with gout prior to and following diagnosis: case-control study. Ann Rheum Dis. 2016;75(1):210-7. doi: 10.1136/annrheumdis-2014-206410..
DOI: 10.1136/annrheumdis-2014-206410
Singh JA. When gout goes to the heart: does gout equal a cardiovascular disease risk factor? Annals of the Rheumatic Diseases. 2015;74(4):631-634. doi:10.1136/annrheumdis-2014-206432..
DOI: 10.1136/annrheumdis-2014-206432
Zhao J., Chen H., Liu N., Chen J., Gu Y., Chen J. & Yang K. Role of Hyperhomocysteinemia and Hyperuricemia in Pathogenesis of Atherosclerosis. Journal of Stroke and Cerebrovascular Diseases. 2017;26(12):2695-2699. doi:10.1016/j.jstrokecer-ebrovasdis.2016.10.012..
DOI: 10.1016/j.jstrokecer-ebrovasdis.2016.10.012
Zhou Y., Zhao M., Pu Z., Xu G. & Li X. Relationship between oxidative stress and inflammation in hyperuricemia. Medicine. 2018;97(49):e13108. doi:10.1097/md.0000000000013108..
DOI: 10.1097/md.0000000000013108
Johnson RJ., Nakagawa T., Sanchez-Lozada L.G., et al. Sugar, uric acid, and the etiology of diabetes and obesity. Diabetes. 2013;62:3307-3315. doi: 10.2337/db12-1814..
DOI: 10.2337/db12-1814
Choi H.K., Ford E.S., Li C., Curhan G. Prevalence of the metabolic syndrome in patients with gout: the Third National Health and Nutrition Examination Survey. Arthritis Rheum. 2007;57(1):109-15. doi: 10.1002/art.22466..
DOI: 10.1002/art.22466
Kuwabara M., Borghi C., Cicero A.F.G., Hisatome I., Niwa K., Ohno M., Lanaspa M.A. Elevated serum uric acid increases risks for developing high LDL cholesterol and hypertriglyceridemia: A five-year cohort study in Japan. International Journal of Cardiology. 2018;261:183-188. doi: 10.1016/j.ijcard.2018.03.045..
DOI: 10.1016/j.ijcard.2018.03.045
Feig D.I. & Johnson RJ. Hyperuricemia in Childhood Primary Hypertension. Hypertension. 2003;42(3):247-252. doi:10.1161/01.hyp.0000085858.66548.59..
DOI: 10.1161/01.hyp.0000085858.66548.59
Feig D.I., Soletsky B. & Johnson RJ. Effect of Allopurinol on Blood Pressure of Adolescents With Newly Diagnosed Essential Hypertension. JAMA. 2008;300(8):924. doi: 10.1001/jama.300.8.924..
DOI: 10.1001/jama.300.8.924
Grayson PC., Kim S.Y., LaValley M. & Choi H.K. Hyperuricemia and incident hypertension: A systematic review and meta-analysis. Arthritis Care & Research. 2010;63(1):102-110. doi: 10.1002/acr.20344..
DOI: 10.1002/acr.20344
Perez-Ruiz F., Martinez-Indart L., Carmona L., Herrero-Beites A.M., Pijoan J.I. & Krishnan E. Tophaceous gout and high level of hyperuricae-mia are both associated with increased risk of mortality in patients with gout. Annals of the Rheumatic Diseases. 2013;73(1):177-182. doi: 10.1136/annrheumdis-2012-202421..
DOI: 10.1136/annrheumdis-2012-202421
Елисеев М.С., Денисов И.С., Маркелова Е.И. и др. Независимые факторы риска развития тяжелых сердечно-сосудистых осложнений у мужчин с подагрой: результаты 7-летнего проспективного наблюдения. Терапевтический архив. 2017;89(5):10-9. doi: 10.17116/ter-arkh201789510-19..
DOI: 10.17116/ter-arkh201789510-19
Елисеев М.С., Денисов И.С., Маркелова Е.И. и др. Независимые факторы риска развития тяжелых сердечно-сосудистых осложнений у мужчин с подагрой: результаты 7-летнего проспективного наблюдения. Терапевтический архив. 2017;89(5):10-9. doi: 10.17116/ter-arkh201789510-19..
DOI: 10.17116/ter-arkh201789510-19. (In Russ)
Zhang C.-H., Huang D.-S., Shen D., Zhang L.-W., Ma Y-J., Wang Y-M. & Sun H.-Y. Association Between Serum Uric Acid Levels and Atrial Fibrillation Risk. Cellular Physiology and Biochemistry. 2016;38(4):1589-1595. doi: 10.1159/000443099..
DOI: 10.1159/000443099
Singh JA. & Cleveland J.D. Comparative effectiveness of allopurinol and febuxostat for the risk of atrial fibrillation in the elderly: a propensitymatched analysis of Medicare claims data. European Heart Journal. 2019. doi: 10.1093/eur-heartj/ehz154..
DOI: 10.1093/eur-heartj/ehz154
White W.B., Saag K.G., Becker M.A., et al. Cardiovascular safety of febuxostat or allopurinol in patients with gout. N Engl J Med. 2018;378:1200-1210. doi: 10.1016/j.ahj.2012.04.011..
DOI: 10.1016/j.ahj.2012.04.011
Choi H., Neogi T., Stamp L., et al. Implications of the cardiovascular safety of febuxostat and allopurinol in patients with gout and cardiovascular morbidities (CARES) trial and associated FDA public safety alert. Arthritis Rheumatol. 2018 Nov;70(11):1702-1709. doi: 10.1002/art.40583..
DOI: 10.1002/art.40583
Елисеев М.С. Сердечно-сосудистая безопасность фебуксостата. Анализ исследования CARES. Современная ревматология. 2018;12(4):42-6. doi: 10.14412/1996-7012-2018-4-42-46..
DOI: 10.14412/1996-7012-2018-4-42-46
Елисеев М.С. Сердечно-сосудистая безопасность фебуксостата. Анализ исследования CARES. Современная ревматология. 2018;12(4):42-6. doi: 10.14412/1996-7012-2018-4-42-46..
DOI: 10.14412/1996-7012-2018-4-42-46. (In Russ)
Huang H., Huang B., Li Y., Huang Y., Li J., Yao H., Wang J. Uric acid and risk of heart failure: a systematic review and meta-analysis. European Journal of Heart Failure. 2013;16(1):15-24. doi: 10.1093/eurjhf/hft132..
DOI: 10.1093/eurjhf/hft132
Zhang M., Solomon D.H., Desai R.J., Kang E.H., Liu J., Neogi T., & Kim S.C. Assessment of Cardiovascular Risk in Older Patients with Gout Initiating Febuxostat versus Allopurinol: A Population-Based Cohort Study. Circulation. 2018. doi: 10.1161/CIRCULATIONAHA.118.033992..
DOI: 10.1161/CIRCULATIONAHA.118.033992
Chou H.W., Chiu H.T., Tsai C.W. et al. Comparative effectiveness of allopurinol, febuxostat and benz-bromarone on renal function in chronic kidney disease patients with hyperuricemia: a 13-year inception cohort study. Nephrol Dial Transplant. 2017 Nov 17. doi: 10.1093/ndt/gfx313..
DOI: 10.1093/ndt/gfx313
Gunawardhana L. et al. Efficacy and safety of febuxostat extended release and immediate release in patients with gout and moderate renal impairment: phase II placebo-controlled study. Arthritis Research & Therapy. 2018;20:99.
Juge PA., et al. Efficacy and safety of febuxostat in 73 gouty patients with stage 4/5 chronic kidney disease: A retrospective study of 10 centers. Joint Bone Spine. 2017;84(5):595-598. doi: 10.1016/j.jbspin.2016.09.020..
DOI: 10.1016/j.jbspin.2016.09.020
Kojima S. et al. Febuxostat for Cerebral and Cardiorenovascular Events PrEvEntion StuDy (FREED) investigators. Eur Heart J. 2019 Mar 7;pii: ehz119. doi: 10.1093/eurheartj/ehz119..
DOI: 10.1093/eurheartj/ehz119
Ranieri L., Contero C., Peral M.-L., Calabuig I., Zapater P. & Andres M. Impact of diuretics on the urate lowering therapy in patients with gout: analysis of an inception cohort. Arthritis Research & Therapy. 2018;20(1). doi:10.1186/s13075-018-1559-2..
DOI: 10.1186/s13075-018-1559-2